Search

Displaying results 3581 - 3590 of 7897 in total
  1. Drug

    BBM-H803

    go.drugbank.com/drugs/DB17700
    Investigational

    It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene. … BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed.

  2. Drug

    Hu-rhEGF-rP64k/Mont

    go.drugbank.com/drugs/DB15781
    Investigational

    Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated

  3. Drug

    CERE-120

    go.drugbank.com/drugs/DB05637
    Investigational

    CERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor.

  4. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer.

  5. Drug

    Pidotimod

    go.drugbank.com/drugs/DB11364
    Investigational

    Pidotimod is a synthetic dipeptide with immunomodulatory properties.[A7956]

    Products: TOPIMOL
  6. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. … Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan.

    International brands: Av-Cor
  7. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  8. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  9. Drug

    CT103A

    go.drugbank.com/drugs/DB18180
    Investigational

    CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

  10. Drug

    CT120

    go.drugbank.com/drugs/DB18181
    Investigational

    CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.